Skip directly to Accessibility Notice

How to Purchase

Individual Investors

Subscribe to email updates

Subscribe Now

Financial Professionals

GNRX
VanEck Vectors Generic Drugs ETF

This Fund is expected to cease trading at market close on April 5, 2019. Shareholders who do not sell their holdings on or before April 5, 2019 and continue to hold their shares through the liquidation date are expected to receive a liquidating distribution on or about April 12, 2019. Please see the press release and FAQ below for more information.

Press Release
FAQ

Fund Description

VanEck Vectors® Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.

 
 

  • Fund Ticker

    GNRX
  • Exchange

    NASDAQ
  • Commencement

    01/12/2016
  • ETF Structure

    Physical
  • Administrator

    Van Eck Associates
  • Custodian

    Bank of New York Mellon
  • Index Ticker

    IGNRXT
  • Index Rebalancing

    Semi-Annual

 
as of 03/22/19

  • 30-Day SEC Yield1

    0.43%
  • Total Net Assets

    $3.3M
  • Number of Holdings

    39
  • Options

    Expected
  • Gross Expense Ratio2

    3.33%
  • Net Expense Ratio/TER2

    0.55%
  • Distribution Frequency

    Annual
  • Next Distribution Date

    12/20/19

Index Key Points

Underlying Index: Indxx Global Generics & New Pharma Index (IGNRXT)

The Index comprises:

The Index is a rules based, modified capitalization weighted index. The Index includes exchange-listed companies, on a global basis, that derive a significant proportion of their revenues (or that have the potential to derive a significant proportion of their revenues) from the generic drug industry, or that have a primary business focus on the generic drug industry. The generic drug industry, as defined by the Index Provider, includes any company involved in the research, development, production, manufacturing or sale of generics, supergenerics, biosimilars, biobetters or their active pharmaceutical ingredients (“APIs”).

Companies eligible for inclusion in Index:

  • Market cap exceeding $1 billion as of the last Friday in February and August 
  • Average daily-trading volume of at least $2 million per day over the last six months 
  • Traded on 90% of the days over the last three months

Index provider:

Indxx, LLC

Index Profile

  • Ticker

    IGNRXT
  • Inception Date

    11/05/2015
  • Rebalance Frequency

    Semi-Annual

Index Top 10 Constituents (%) as of 02/28/19 Download All Index Constituents

Total Constituents: 39
Swipe
to view
full data
Constituent Name
Ticker
Weightings (%)
Pfizer Inc
PFE US
9.30
Iqvia Holdings Inc
IQV US
8.87
Lonza Group Ag-Reg
LONN VX
6.65
Celltrion Inc
068270 KS
6.58
Teva Pharmaceutical-Sp Adr
TEVA US
5.18
Sun Pharmaceutical Indus
SUNP IN
4.29
Mylan Nv
MYL US
4.03
Sino Biopharmaceutical
1177 HK
3.44
Kyowa Hakko Kirin Co Ltd
4151 JP
3.40
Cspc Pharmaceutical Group Lt
1093 HK
3.34
Top 10 Total (%) 55.08
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Index Country Weightings (%) as of 02/28/19

  • Country

    Weightings (%)
  • UNITED STATES

    36.1
  • INDIA

    15.8
  • SOUTH KOREA

    8.0
  • JAPAN

    7.7
  • SWITZERLAND

    6.6
  • CHINA

    6.5
  • ISRAEL

    6.4
  • HONG KONG

    3.4
  • IRELAND

    2.4
  • UNITED KINGDOM

    1.6
  • INDONESIA

    1.6
  • SOUTH AFRICA

    1.4
  • FINLAND

    1.1
  • HUNGARY

    1.1

Index Sector Weightings (%) as of 02/28/19

  • Sector

    Weightings (%)
  • Health Care

    96.9
  • Materials

    3.1